| Bioactivity | BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 impairs the anchorage-independent growth of KEAP1-mutant cancer cells[1]. | ||||||||||||
| Invitro | BPK-29 substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers[1]. | ||||||||||||
| Name | BPK-29 | ||||||||||||
| CAS | 2143467-62-1 | ||||||||||||
| Formula | C26H32ClN3O3 | ||||||||||||
| Molar Mass | 470.00 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Bar-Peled L, et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell. 2017 Oct 19;171(3):696-709.e23. |
BPK-29
CAS: 2143467-62-1 F: C26H32ClN3O3 W: 470.00
BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) inter
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.